Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)

NCT02609048 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02609048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02609048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
November 4, 2015
Completion date
July 1, 2016
Enrollment
41 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cirrhosis (pbc)